Simulations Plus has announced strategic partnership programmes with three pharmaceutical businesses to advance AI-enabled modelling in drug development. The partnerships aim …
Corcept Therapeutics has secured US approval for its selective glucocorticoid receptor agonist, Lifyorli (relacorilant), in ovarian cancer more than three …
The US Food and Drug Administration (FDA) will convene a public hearing intended to obtain feedback on its Commissioner's National …
US-based neurotechnology company Cognito Therapeutics has collaborated with Ochsner Health to establish the Brain Health Collaboratory, aiming to advance new …
Daiichi Sankyo has entered a strategic collaboration with Tempus AI to expedite the clinical development and differentiation of an antibody …
US-based neurotechnology company Cognito Therapeutics has collaborated with Ochsner Health to establish the Brain Health Collaboratory, aiming to advance new …
Daiichi Sankyo has entered a strategic collaboration with Tempus AI to expedite the clinical development and differentiation of an antibody …
On 12 May 2025, US President Donald Trump signed an executive order directing the US Department of Health and Human …
UCB has chosen Georgia as the home for its new biologics manufacturing facility, cementing its legacy in the state and …
Outcomes for liver cancer patients are highly stage dependent. Interventions designed to be curative, such as minimally invasive ablation, tumour …
MSD will buy cancer specialist Terns Pharmaceuticals in a deal worth $6.7bn, as the drugmaker continues its string of multibillion-dollar …
Pharmaceutical R&D is falling increasingly to artificial intelligence (AI)-guided autonomous laboratories, and the people behind them say the role of …
Viz.ai has entered a collaboration with Alnylam to advance earlier identification and streamline diagnosis for cardiac amyloidosis, an underdiagnosed cause …
Merck & Co (MSD) has signed a multi-year research collaboration with Quotient Therapeutics to discover new drug targets for inflammatory …
On 23 February, Gilead Sciences announced its $7.8bn acquisition of Arcellx, primarily to secure rights to anitocabtagene autoleucel (anito-cel), an …
